Cash funds operations well into 2029, taking the usual biotech dilution worry off the table for now. Amtagvi demand narrowed the quarterly operating loss to $24.0 million from $94.9 million a year ago, and management reaffirmed full-year product revenue of $410 million to $420 million.
Latest Activity
IOVA Coverage
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
A relative unknown, if you don’t watch the biotherapeutics industry, Iovance Biotherapeutics (NASDAQ:IOVA | IOVA Price Prediction) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing…
Stock Offerings Prompt Big Insider Buying
Public offerings of stock tempted some insider buying, and one insider stepped up to support a struggling online delivery service provider.
Cathie Wood’s ARK Invest Sells Over 300,000 Shares of Iovance Bio
One of Cathie Wood's ARK Invest funds sold over 300,000 shares of cancer-focused biopharma startup Iovance Bio on August 26.
Cathie Wood’s ARK Invest Sells Over 125,000 Shares of Iovance Bio
One of Cathie Wood's ARK Invest funds bought over 125,000 shares of Iovance Bio on August 25.
Cathie Wood’s ARK Invest Buys Over 1 Million Shares of Iovance Bio
A couple of Cathie Wood's Ark Invest funds bought over 1 million shares of Iovance Bio on May 20.
Merck, Micron, Nvidia, Target and More Thursday Afternoon Analyst Calls
24/7 Wall St. looks at some big analyst calls that we have seen so far on Thursday, including LendingTree, Merck, Micron Technology, Nvidia and Target.
10 Very Strong Stocks Thriving in a Very Crummy Stock Market
These 10 stocks have incredibly strong stock charts and strong performance despite the crummy market conditions that have been seen so far in 2020.